Annual EBIT
-$9.28 M
+$2.80 M+23.20%
June 30, 2024
Summary
- As of February 8, 2025, AYTU annual earnings before interest & taxes is -$9.28 million, with the most recent change of +$2.80 million (+23.20%) on June 30, 2024.
- During the last 3 years, AYTU annual EBIT has risen by +$28.96 million (+75.72%).
- AYTU annual EBIT is now -19695.31% below its all-time high of -$46.90 thousand, reached on August 31, 2007.
Performance
AYTU EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
$2.49 M
+$10.42 M+131.45%
September 30, 2024
Summary
- As of February 8, 2025, AYTU quarterly earnings before interest & taxes is $2.49 million, with the most recent change of +$10.42 million (+131.45%) on September 30, 2024.
- Over the past year, AYTU quarterly EBIT has increased by +$8.68 million (+140.26%).
- AYTU quarterly EBIT is now -18.30% below its all-time high of $3.05 million, reached on June 30, 2023.
Performance
AYTU Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
-$5.29 M
+$8.68 M+62.15%
September 30, 2024
Summary
- As of February 8, 2025, AYTU TTM earnings before interest & taxes is -$5.29 million, with the most recent change of +$8.68 million (+62.15%) on September 30, 2024.
- Over the past year, AYTU TTM EBIT has increased by +$11.34 million (+68.19%).
- AYTU TTM EBIT is now -278215.79% below its all-time high of -$1900.00, reached on May 31, 2006.
Performance
AYTU TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
AYTU EBIT Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | +23.2% | +140.3% | +68.2% |
3 y3 years | +75.7% | +130.2% | +87.7% |
5 y5 years | +44.9% | +116.6% | +81.1% |
AYTU EBIT Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3-year | at high | +75.7% | -18.3% | +122.1% | -76.5% | +89.4% |
5 y | 5-year | at high | +75.7% | -18.3% | +116.1% | -76.5% | +89.4% |
alltime | all time | <-9999.0% | +75.7% | -18.3% | +116.1% | <-9999.0% | +89.4% |
Aytu BioPharma EBIT History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Sep 2024 | - | $2.49 M(-131.4%) | -$5.29 M(-62.1%) |
Jun 2024 | -$9.28 M(-23.2%) | -$7.92 M(+256.9%) | -$13.97 M(+366.3%) |
Mar 2024 | - | -$2.22 M(-193.9%) | -$3.00 M(-70.2%) |
Dec 2023 | - | $2.36 M(-138.2%) | -$10.07 M(-39.4%) |
Sep 2023 | - | -$6.19 M(-303.0%) | -$16.63 M(+37.5%) |
Jun 2023 | -$12.09 M(-66.5%) | $3.05 M(-132.8%) | -$12.09 M(-45.7%) |
Mar 2023 | - | -$9.29 M(+121.6%) | -$22.24 M(-0.7%) |
Dec 2022 | - | -$4.19 M(+153.7%) | -$22.41 M(-24.1%) |
Sep 2022 | - | -$1.65 M(-76.7%) | -$29.51 M(-18.3%) |
Jun 2022 | -$36.10 M(-5.6%) | -$7.10 M(-24.9%) | -$36.10 M(-18.8%) |
Mar 2022 | - | -$9.46 M(-16.2%) | -$44.45 M(-11.1%) |
Dec 2021 | - | -$11.29 M(+37.0%) | -$50.02 M(+16.4%) |
Sep 2021 | - | -$8.25 M(-46.6%) | -$42.99 M(+12.2%) |
Jun 2021 | -$38.24 M(+113.4%) | -$15.45 M(+2.8%) | -$38.30 M(+37.1%) |
Mar 2021 | - | -$15.03 M(+252.5%) | -$27.94 M(+60.6%) |
Dec 2020 | - | -$4.26 M(+19.8%) | -$17.40 M(-3.9%) |
Sep 2020 | - | -$3.56 M(-30.2%) | -$18.10 M(-6.1%) |
Jun 2020 | -$17.92 M(+6.4%) | -$5.09 M(+13.7%) | -$19.28 M(+2.7%) |
Mar 2020 | - | -$4.48 M(-9.8%) | -$18.77 M(+1.0%) |
Dec 2019 | - | -$4.97 M(+4.9%) | -$18.58 M(+2.3%) |
Sep 2019 | - | -$4.74 M(+3.4%) | -$18.16 M(+7.8%) |
Jun 2019 | -$16.85 M(-5.6%) | -$4.58 M(+6.5%) | -$16.85 M(+4.7%) |
Mar 2019 | - | -$4.30 M(-5.5%) | -$16.09 M(-7.9%) |
Dec 2018 | - | -$4.55 M(+33.2%) | -$17.46 M(+3.3%) |
Sep 2018 | - | -$3.42 M(-10.7%) | -$16.91 M(-3.6%) |
Jun 2018 | -$17.84 M(-10.7%) | -$3.83 M(-32.5%) | -$17.55 M(-6.8%) |
Mar 2018 | - | -$5.67 M(+42.0%) | -$18.82 M(+2.9%) |
Dec 2017 | - | -$3.99 M(-1.5%) | -$18.29 M(-2.3%) |
Sep 2017 | - | -$4.06 M(-20.5%) | -$18.72 M(-6.3%) |
Jun 2017 | -$19.97 M(-12.0%) | -$5.10 M(-0.7%) | -$19.97 M(-31.4%) |
Mar 2017 | - | -$5.14 M(+16.0%) | -$29.11 M(+7.1%) |
Dec 2016 | - | -$4.43 M(-16.6%) | -$27.17 M(+5.2%) |
Sep 2016 | - | -$5.31 M(-62.7%) | -$25.83 M(+13.9%) |
Jun 2016 | -$22.69 M(+197.3%) | -$14.23 M(+344.9%) | -$22.69 M(+113.9%) |
Mar 2016 | - | -$3.20 M(+3.5%) | -$10.61 M(+15.1%) |
Dec 2015 | - | -$3.09 M(+43.0%) | -$9.21 M(+49.9%) |
Sep 2015 | - | -$2.16 M(+0.5%) | -$6.15 M(+53.9%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Jun 2015 | -$7.63 M(>+9900.0%) | -$2.15 M(+19.1%) | -$3.99 M(+115.5%) |
Mar 2015 | - | -$1.81 M(>+9900.0%) | -$1.85 M(+3875.8%) |
Feb 2015 | - | -$9400.00(-38.6%) | -$46.60 K(-19.4%) |
Nov 2014 | - | -$15.30 K(+41.7%) | -$57.80 K(+0.5%) |
Aug 2014 | -$57.50 K(-99.1%) | -$10.80 K(-2.7%) | -$57.50 K(+3.0%) |
Jun 2014 | -$6.35 M(>+9900.0%) | - | - |
May 2014 | - | -$11.10 K(-46.1%) | -$55.80 K(-1.6%) |
Feb 2014 | - | -$20.60 K(+37.3%) | -$56.70 K(+16.4%) |
Nov 2013 | - | -$15.00 K(+64.8%) | -$48.70 K(-7.2%) |
Aug 2013 | -$52.40 K(-7.1%) | -$9100.00(-24.2%) | -$52.50 K(-13.4%) |
May 2013 | - | -$12.00 K(-4.8%) | -$60.60 K(+1.5%) |
Feb 2013 | - | -$12.60 K(-33.0%) | -$59.70 K(+6.0%) |
Nov 2012 | - | -$18.80 K(+9.3%) | -$56.30 K(-0.2%) |
Aug 2012 | -$56.40 K(-57.8%) | -$17.20 K(+55.0%) | -$56.40 K(-48.7%) |
May 2012 | - | -$11.10 K(+20.7%) | -$109.90 K(-7.5%) |
Feb 2012 | - | -$9200.00(-51.3%) | -$118.80 K(-12.6%) |
Nov 2011 | - | -$18.90 K(-73.3%) | -$135.90 K(+1.7%) |
Aug 2011 | -$133.60 K(+135.6%) | -$70.70 K(+253.5%) | -$133.60 K(+75.8%) |
May 2011 | - | -$20.00 K(-24.0%) | -$76.00 K(+8.9%) |
Feb 2011 | - | -$26.30 K(+58.4%) | -$69.80 K(+27.4%) |
Nov 2010 | - | -$16.60 K(+26.7%) | -$54.80 K(-3.4%) |
Aug 2010 | -$56.70 K(+1.6%) | -$13.10 K(-5.1%) | -$56.70 K(+5.0%) |
May 2010 | - | -$13.80 K(+22.1%) | -$54.00 K(+10.2%) |
Feb 2010 | - | -$11.30 K(-38.9%) | -$49.00 K(-7.2%) |
Nov 2009 | - | -$18.50 K(+77.9%) | -$52.80 K(-5.4%) |
Aug 2009 | -$55.80 K(+1.5%) | -$10.40 K(+18.2%) | -$55.80 K(-2.4%) |
May 2009 | - | -$8800.00(-41.7%) | -$57.20 K(-12.9%) |
Feb 2009 | - | -$15.10 K(-29.8%) | -$65.70 K(+7.4%) |
Nov 2008 | - | -$21.50 K(+82.2%) | -$61.20 K(+11.5%) |
Aug 2008 | -$55.00 K(+17.3%) | -$11.80 K(-31.8%) | -$54.90 K(+1.1%) |
May 2008 | - | -$17.30 K(+63.2%) | -$54.30 K(+7.1%) |
Feb 2008 | - | -$10.60 K(-30.3%) | -$50.70 K(-8.0%) |
Nov 2007 | - | -$15.20 K(+35.7%) | -$55.10 K(+17.5%) |
Aug 2007 | -$46.90 K | -$11.20 K(-18.2%) | -$46.90 K(+31.4%) |
May 2007 | - | -$13.70 K(-8.7%) | -$35.70 K(+49.4%) |
Feb 2007 | - | -$15.00 K(+114.3%) | -$23.90 K(+168.5%) |
Nov 2006 | - | -$7000.00(+268.4%) | -$8900.00(+368.4%) |
May 2006 | - | -$1900.00 | -$1900.00 |
FAQ
- What is Aytu BioPharma annual earnings before interest & taxes?
- What is the all time high annual EBIT for Aytu BioPharma?
- What is Aytu BioPharma annual EBIT year-on-year change?
- What is Aytu BioPharma quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Aytu BioPharma?
- What is Aytu BioPharma quarterly EBIT year-on-year change?
- What is Aytu BioPharma TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Aytu BioPharma?
- What is Aytu BioPharma TTM EBIT year-on-year change?
What is Aytu BioPharma annual earnings before interest & taxes?
The current annual EBIT of AYTU is -$9.28 M
What is the all time high annual EBIT for Aytu BioPharma?
Aytu BioPharma all-time high annual earnings before interest & taxes is -$46.90 K
What is Aytu BioPharma annual EBIT year-on-year change?
Over the past year, AYTU annual earnings before interest & taxes has changed by +$2.80 M (+23.20%)
What is Aytu BioPharma quarterly earnings before interest & taxes?
The current quarterly EBIT of AYTU is $2.49 M
What is the all time high quarterly EBIT for Aytu BioPharma?
Aytu BioPharma all-time high quarterly earnings before interest & taxes is $3.05 M
What is Aytu BioPharma quarterly EBIT year-on-year change?
Over the past year, AYTU quarterly earnings before interest & taxes has changed by +$8.68 M (+140.26%)
What is Aytu BioPharma TTM earnings before interest & taxes?
The current TTM EBIT of AYTU is -$5.29 M
What is the all time high TTM EBIT for Aytu BioPharma?
Aytu BioPharma all-time high TTM earnings before interest & taxes is -$1900.00
What is Aytu BioPharma TTM EBIT year-on-year change?
Over the past year, AYTU TTM earnings before interest & taxes has changed by +$11.34 M (+68.19%)